ACTC Advanced Cell Technology, Inc., a biotechnology

New Post Public Reply Private Reply Replies (0) Message Board

Apr 12, 2013 at 7:50 PM

ACTC Advanced Cell Technology, Inc., a biotechnology company, focuses on the development and commercialization of human embryonic, induced Pluripotency (iPS), and adult stem cell technology in the field of regenerative medicine Operations The company’s business is focused on both the development and commercialization of adult stem cell therapies and therapies based on cells derived from embryonic stem (ES) cells or other potentially totipotent stem cell technologies. The company’s adult stem cell-based products are specifically targeted at therapies for heart and other cardiovascular disease and are at a more advanced stage of development than its human ES cell based technologies. Its first human ES cell-based product, retinal pigmented epithelial cells, have entered Phase I clinical trials and various patients have already been treated. The company’s intellectual property includes patent rights and applications for specific applications of stem cell technology in producing retinal pigment epithelium (RPE) cells, hemangioblasts, myoblast stem cells, and various methods and compositions for the use of these technologies and derived cells in treating retinal and other eye disease, inflammatory and autoimmune diseases, and heart disease, as well as to provide agents for wound healing and replacement of blood components. Human ES Cell Programs The company’s research and technologies are focused on solving this obstacle by creating stem cell therapeutics with compatible tissues or which can be used in immunopriveleged or immunosuppressed sites of transplantation in patients. Compatible tissues are referred to as being histocompatible. The company has developed an alternative to inner cell mass (ICM)-derivation of human embryonic cell (hESC) - a method which utilizes single cell biopsy to remove a single blastomere from a 4-8 cell preembryo in a manner which does not result in the destruction of the preembryo. The company’s human ES cell technologies comprise cellular reprogramming and pluripotent stem cell technologies to produce cells that have the proliferative capacity of ES cells with therapeutic application and compatible with the patient. Cell Therapy Research Programs The company’s research in this area includes projects focusing on developing different cell types that may be used in the future to treat a range of diseases. Its researchers have generated stable RPE cell lines for use in its clinical retinal program and are working on projects to generate stable cell lines with particular focus on blood lineage and vascular epithelial cell lines from hemangioblast cells. Its cell therapy research programs include RPE and hemangioblast programs. The hemangioblast program is in preclinical development. Adult Stem Cell Program The company’s adult stem cell-based program is developing an autologous myoblast transplantation therapy delivered using a minimally invasive catheter injection system to restore cardiac function in patients with advanced heart disease. The key target for the therapy would be heart failure patients with New York Heart Association (NYHA) scores Class II to IV. The company's therapy could also benefit patients supported on ventricular assistance devices and potential additional indications, such as acute myocardial infarction, peripheral artery disease, and non-cardiac tissue repair. Intellectual Property The company’s research and development is supported by an intellectual property portfolio. It owns or has licenses to approximately 35 patents and has approximately 170 patent applications pending worldwide in the field of regenerative medicine and stem cell therapy. The company also has non-exclusive rights to a portfolio of patents and patent applications that support its core intellectual property. Collaborative Agreements In 2011, the company entered into a definitive collaborative agreement with Roslin Cells LTD (Roslin Cells) of Scotland. The company would work together to establish a bank of Good Manufacturing Practice (GMP)-grade human ES cell (hESC) lines using its patented, proprietary ‘single-cell blastomere’ technique for deriving hESC lines without destroying embryos. Regulations The company, in addition to safety regulations enforced by the US Food and Drug Administration (FDA), is also subject to regulations under the Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substances Control Act, and other present and potential future and federal, state, local, and foreign regulations.

Ocata Therapeutics Inc. (OCAT) Stock Research Links

OCAT Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

PhoenixAI and Cloudera's Strategic Partnership Shifts Data Landscape

Time to Embrace Change: PhoenixAI Teams with Cloudera Mention the word 'partnership' in the tech space, and it's often as common as a cup of joe at dawn—but this one truly shakes things up. We're talking about PhoenixAI hitching its wagon to Cloudera's startup circus, a merging of fire and steel in AI-driven database management. With PhoenixAI strutting its stuff on the...

Aviator Nation Teams with NFL for 2026 Collection Launch

In a move blending sports with a dash of retro flair, Aviator Nation's dropping its first NFL-licensed collection. They’re looking to serve up a blend of vintage vibes and team spirit. Aviator Nation's New Venture Launching their collection on September 24th, 2026, Aviator Nation takes a dive deeper into sports licensing, after scoring a touchdown (literally!) with an...

Quantum Sky's Strategic Leadership Overhaul Targets Growth

Executive Shake-Up Aims for Stronger Federal Market Alignment Buckle up, folks—there's some major chess-piecing happening at Quantum Sky. They've just named not one or two, but three executive bigwigs to head up their core business groups. This isn’t just some ceremonial reshuffle. Nah, it’s bigger. They're redefining how they tackle the Department of War, Intel &...

Navigating Hit and Run Protocols in St. Tammany Parish

When the Driver Disappears: Steps Forward Hit and run accidents can leave you feeling abandoned and unsure of what to do. In St. Tammany Parish, this scenario is all too familiar. Personal Injury Attorney Ross F. Lagarde cuts through the chaos, offering a clear path for those caught in this nightmare, explained in HelloNation's comprehensive guide. Prioritize Safety and...

Miguel Pantoja: Wiring a Second Chance Beyond Bars

A Second Shot with Electric Dreams Miguel Pantoja, once on the rocky road of life choices, now lights up Northern California with his spark — quite literally. Walking out of federal prison, his mind was set as firmly as a bolt: first stop was a burger, second was a plan to transform his past into a new beginning. That path took him to UEI College in Sacramento, where...

Infrared Imaging Expands with AI, SWIR: Tech Trends

Infrared Imaging: The Backbone of Future Tech Kinda wild how infrared imaging's become a hot topic in tech circles. With the market expected to jump from USD 9.2 billion in 2026 to a hefty USD 12.6 billion by 2031, averaging a 6.4% growth rate, there's plenty to chew on. Even if you ain't the analytical type, it ain't hard to spot where the money's flowing. Infrared's...

Mattamy Homes Earns Spot as Top Workplace in Jacksonville

Jacksonville's Housing Scene Gets a Boost In a world where everyone seems bent on working down to the bone to climb some imaginary corporate ladder, here comes Jacksonville's own Mattamy Homes with a news flash—it's possible to work, live, and still smile at the end of the day. Recently, they earned themselves a coveted spot among the best workplaces in Jacksonville for...

BeyondCPG Accelerator Launches Seventh Growth Program

Fresh Faces in Conscious Consumerism There's nothing quite like an early morning jolt of caffeine mixed with the buzz of innovation in the air. BeyondCPG, a heavyweight in the conscious products arena, has cracked open the doors to its seventh round of powerhouse brand-boosting with the launch of its new Accelerator Track 7. They're mixing heart with hustle to give...

PostalAnnex Lands at Stanford with New Service Hub

PostalAnnex Makes a Strategic Stanford Move It's not every day you see a company nestling into a place like Stanford University. Annex Brands has just opened its latest PostalAnnex location, a stone’s throw from the academic hustle and bustle of the Stanford campus. The geeky vibe of students and professors rushing with deadlines matches well with the efficient service...

VERTESS Tops Axial's 2026 Healthcare M&A Advisor List

Strength Takes Top Spot in Healthcare M&A VERTESS has grabbed the gold medal in healthcare sell-side M&A, something that didn't just fall from the sky. Axial gave them the nod as the cream of the crop among the Top 50 Lower Middle Market Healthcare M&A Advisors for 2026. Evaluating the Strengths that Set VERTESS Apart When Axial, that private deal network that's all about...